Hostname: page-component-7c8c6479df-fqc5m Total loading time: 0 Render date: 2024-03-28T10:55:43.570Z Has data issue: false hasContentIssue false

Impact of lithium alone or in combination with haloperidol on oxidative stress parameters and cell viability in SH-SY5Y cell culture

Published online by Cambridge University Press:  19 August 2015

Oliwia Gawlik-Kotelnicka*
Affiliation:
Department of Affective and Psychotic Disorders, Medical University of Lodz, Czechoslowacka, Lodz, Poland
Wojciech Mielicki
Affiliation:
Department of Pharmaceutical Biochemistry, Medical University of Lodz, Muszynskiego, Lodz, Poland
Jolanta Rabe-Jabłońska
Affiliation:
Department of Affective and Psychotic Disorders, Medical University of Lodz, Czechoslowacka, Lodz, Poland
Jerry Lazarek
Affiliation:
Department of Affective and Psychotic Disorders, Medical University of Lodz, Czechoslowacka, Lodz, Poland
Dominik Strzelecki
Affiliation:
Department of Affective and Psychotic Disorders, Medical University of Lodz, Czechoslowacka, Lodz, Poland
*
Oliwia Gawlik-Kotelnicka, 90-339 Lodz, ul. Wilcza 2 m. 51, Poland. Tel: +48 693 876 422; Fax: +48 42 675 74 03; E-mail: oliwia.gawlik@umed.lodz.pl

Abstract

Background

It has been reported that lithium may inhibit lipid peroxidation and protein oxidation. Lithium salts also appear to stimulate cell proliferation, increase neurogenesis, and delay cell death. Oxidative stress and neurodegeneration may play an important role in the pathophysiology of bipolar disorder and the disease course thereof. The aim of this research is to estimate the influence of lithium (alone and in combination with haloperidol) on the parameters of oxidative stress and viability of SH-SY5Y cell lines in neutral and pro-oxidative conditions.

Methods

The evaluated oxidative stress parameter was lipid peroxidation. The viability of the cell lines was measured utilising the MTT test.

Results

In neutral conditions, higher levels of thiobarbituric acid reactive substances were observed in those samples which contained both haloperidol and lithium than in other samples. However, these differences were not statistically significant. Cell viability was significantly higher in therapeutic lithium samples than in the controls; samples of haloperidol alone as well as those of haloperidol with lithium did not differ from controls.

Conclusions

The results of our study may indicate that lithium possess neuroprotective properties that may be partly due to antioxidative effects. The combination of lithium and haloperidol may generate increased oxidative stress.

Type
Original Articles
Copyright
© Scandinavian College of Neuropsychopharmacology 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Connolly, KR, Thase, ME The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord 2011;13:PCC.10r01097.Google Scholar
2. Shaldubina, A, Agam, G, Belmaker, RH. The mechanism of lithium action: state of the art, ten years later. Prog Neuro-Psychopharmacol Biol Psychiat 2001;25:855866.Google Scholar
3. Lenox, RH, Frazer, A. Mechanism of action of antidepressants and mood stabilizers. In Davis DL, Charney D, Coyle JT, editors. Neuropsychopharmacology: The Fifth Generation of Progress. Nashville: American College of Neuropsychopharmacology, 2002. p. 11391163.Google Scholar
4. King, TD, Jope, RS. Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport 2005;16:597601.Google Scholar
5. Rybakowski, JK. Lithium in neuropsychiatry: a 2010 update. World J Biol Psychiatry 2011;12:340348.Google Scholar
6. Forlenza, OV, De-Paula, VJ, Diniz, BS. Neuroprotective effects of lithium: implications for the treatment of Alzheimer’s disease and related neurodegenerative disorders. ACS Chem Neurosci 2014;5:443450.Google Scholar
7. Scheuing, L, Chiu, C-T, Liao, H, Linares, G, Chuang, D. Preclinical and clinical investigations of mood stabilizers for Huntington’s disease: what have we learned? Int J Biol Sci 2014;10:10241038.Google Scholar
8. Nunes, PV, Forlenza, OV, Gattaz, WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007;190:359360.Google Scholar
9. Gerhard, T, Devanand, DP, Huang, C, Crystal, S, Olfson, M. Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Br J Psychiatry 2015;207:4651.Google Scholar
10. Terao, T, Nakano, H, Inoue, Y, Okamoto, T, Nakamura, J, Iwata, N. Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:11251128.Google Scholar
11. Forlenza, OV, Diniz, BS, Radanovic, M, Santos, FS, Talib, LL, Gattaz, WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011;198:351356.CrossRefGoogle ScholarPubMed
12. Hernandez, F, Lucas, JJ, Avila, J. GSK3 and tau: two convergence points in Alzheimer’s disease. J Alzheimers Dis 2013;33:S141S144.Google Scholar
13. Phillips, ML, Travis, MJ, Fagiolini, A, Kupfer, DJ. Medication effects in neuroimaging studies of bipolar disorder. Am J Psychiatry 2008;165:313320.Google Scholar
14. de Sousa, RT, Zarate, CA Jr, Zanetti, MV et al Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatr Res 2014;50:3641.Google Scholar
15. Sies, H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82:291295.Google Scholar
16. Mahadik, SP, Mukherjee, S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996;19:117.Google Scholar
17. Rice-Evans, CA, Diplock, AT, Symons, MCR. Techniques in Free Radical Research. Amsterdam, London, New York, Tokyo: Elsevier, 1991.Google Scholar
18. Re, R, Pellegrini, N, Proteggente, A, Pannala, A, Yang, M, Rice-Evans, C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 1999;26:12311237.Google Scholar
19. Berk, M, Kapczinski, F, Andreazza, AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35:804817.Google Scholar
20. Tsai, MC, Huang, TL. Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord 2015;173:2226.CrossRefGoogle Scholar
21. Machado-Vieira, R, Andreazza, AC, Viale, CI et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007;421:3336.Google Scholar
22. Andreazza, AC, Kauer-Sant'Anna, M, Frey, BN et al Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008;111:135144.Google Scholar
23. Bengesser, SA, Lackner, N, Birner, A et al. Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder-gender and obesity effects. J Affect Disord 2014;172C:367374.Google Scholar
24. Kapczinski, F, Frey, BN, Andreazza, AC, Kauer-Sant'Anna, M, Cunha, AB, Post, RM. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 2008;30:243245.Google Scholar
25. Andreazza, AC, Cassini, C, Rosa, AR et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007;41:523529.Google Scholar
26. Marazziti, D, Baroni, S, Picchetti, M et al. Psychiatric disorders and mitochondrial dysfunctions. Eur Rev Med Pharmacol Sci 2012;16:270275.Google Scholar
27. Mahadik, SP, Evans, D, Lal, H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:463493.Google Scholar
28. Buttner, N, Bhattacharyya, S, Walsh, J, Benes, FM. DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia. Schizophr Res 2007;93:3341.Google Scholar
29. Shao, L, Young, LT, Wang, JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005;58:879884.CrossRefGoogle ScholarPubMed
30. Vasconcellos, APS, Nieto, FB, Crema, LM et al. Chronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem Res 2006;31:11411151.CrossRefGoogle Scholar
31. Shin, JH, Cho, SI, Lim, HR et al. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of ALS. Mol Pharmacol 2007;71:965975.Google Scholar
32. Chadha, VD, Bhalla, P, Dhawan, DK. Zinc modulates lithium-induced hepatotoxicity in rats. Liver Int 2008;28:558565.CrossRefGoogle ScholarPubMed
33. Aliyazicioglu, R, Kural, B, Colak, M, Karahan, SC, Ayvaz, S, Deger, O. Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases aterogenic lipids in bipolar disorder. Tohoku J Exp Med 2007;213:7987.Google Scholar
34. Banerjee, U, Dasgupta, A, Rout, JK, Singh, OP. Effects of lithium therapy on Na(+)-K(+)-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012;27:5661.CrossRefGoogle Scholar
35. Khairova, R, Pawar, R, Salvadore, G et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep 2012;5:680682.Google Scholar
36. Parikh, V, Khan, MM, Mahadik, SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003;37:4351.Google Scholar
37. Singh, OP, Chakraborty, I, Dasgupta, A, Datta, S. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J Psychiatry 2008;50:171176.Google Scholar
38. Dietrich-Muszalska, A, Kontek, B, Rabe-Jabłońska, J. Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro. Neuropsychobiology 2011;63:197201.Google Scholar
39. Schmidt, AJ, Hemmeter, UM, Krieg, JC, Vedder, H, Heiser, P. Impact of haloperidol and quetiapine on the expression of genes encoding antioxidant enzymes in human neuroblastoma SHSY5Y cells. J Psychiatr Res 2009;43:818823.Google Scholar
40. Lepping, P, Delieu, J, Mellor, R, Williams, JHH, Hudson, PR, Hunter-Lavin, CJ. Antipsychotic medication and oxidative cell stress: a systematic review. J Clin Psychiatry 2011;72:273285.Google Scholar
41. Soares, JC, Boada, F, Keshavan, MS. Brain lithium measurements with Li magnetic resonance spectroscopy (MRS): a literature review. Eur Neuropsychopharmacol 2000;10:151158.CrossRefGoogle ScholarPubMed
42. Kornhuber, J, Schultz, A, Wiltfang, J et al. Persistence of haloperidol in human brain tissue. Am J Psychiatry 1999;156:885890.Google Scholar
43. Zhao, J, Liu, Y, Wei, X, Yuan, C, Yuan, X, Xiao, X. A novel WD-40 repeat protein WDR26 suppresses H2O2-induced cell death in neural cells. Neurosci Lett 2009;460:6671.Google Scholar
44. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:5563.Google Scholar
45. Abdalla, DSP, Bechara, EJH. The effect of chlorpromazine and Li2CO3 on the superoxide dismutase and glutathione peroxidase activities of rat brain, liver and erythrocytes. Biochem Mol Biol Int 1994;34:10851090.Google Scholar
46. Nciri, R, Allagui, MS, Vincent, C, Murat, JC, Croute, F, El Feki, A. Chronic lithium administration triggers an over-expression of GRP94 stress protein isoforms in mouse liver. Food Chem Toxicol 2010;48:16381643.Google Scholar
47. Kiełczykowska, M, Pasternak, K, Musik, I, Wrońska-Tyra, J, Hordyjewska, A. The influence of different doses of lithium administered in drinking water on lipid peroxidation and the activity of antioxidant enzymes in rats. Polish J Environ Stud 2006;15:747751.Google Scholar
48. Bhalla, P, Dhawan, DK. Protective role of lithium in ameliorating the aluminium-induced oxidative stress and histological changes in rat brain. Cell Mol Neurobiol 2009;29:513521.Google Scholar
49. Chiu, CT, Scheuing, L, Liu, G et al. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int J Neuropsychopharmacol 2014;18:113.Google Scholar
50. Allagui, MS, Nciri, R, Rouhaud, MF, Murat, JC, Feki, A, Croute, F. Long-term exposure to low lithium concentrations stimulates proliferation, modifies stress protein expression pattern and enhances resistance to oxidative stress in SH-SY5Y cells. Neurochem Res 2009;34:453462.Google Scholar
51. Song, C, Killeen, AA, Leonard, BE. Catalase, superoxide dismutase and glutathione peroxidase activity in neutrophils of sham-operated and olfactory-bulbectomised rats following chronic treatment with desipramine and lithium chloride. Neuropsychobiology 1994;30:24.CrossRefGoogle ScholarPubMed
52. Frey, BN, Valvassori, SS, Réus, GZ et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006;31:326332.Google Scholar
53. Macêdo, DS, de Lucena, DF, Queiroz, AI et al. Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 2013;3:230237.Google Scholar
54. Jornada, LK, Valvassori, SS, Steckert, AV et al. Lithium and valproate modulate antioxidant enzymes and prezent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res 2011;45:162168.Google Scholar
55. Albayrak, A, Halici, Z, Polat, B et al. Protective effects of lithium: a new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. Int Immunopharmacol 2013;16:3540.Google Scholar
56. Nciri, R, Allagui, MS, Murat, J-C, Croute, F. Lipid peroxidation, antioxidant activities and stress protein (HSP72/73, GRP94) expression in kidney and liver of rats under lithium treatment. J Physiol Biochem 2012;68:1118.Google Scholar
57. Malhotra, A, Dhawan, DK. Zinc improves antioxidative enzymes in red blood cells and hematology in lithium-treated rats. Nutr Res 2008;28:4350.Google Scholar
58. Sahin, O, Sulak, O, Yavuz, Y et al. Lithium-induced lung toxicity in rats: the effect of caffeic acid phenethyl ester (CAPE). Pathology 2006;38:5862.Google Scholar
59. Cohen, WJ, Cohen, NH. Lithium carbonate, haloperidol, and irreversible brain damage. JAMA 1974;230:12831287.Google Scholar
60. Guynn, RW, Faillace, LA. The effect of the combination of lithium and haloperidol on brain intermediary metabolism in vivo. Psychopharmacology 1979;61:155159.Google Scholar
61. Sawas, AH, Gilbert, JC. Lipid peroxidation as a possible mechanism for the neurotoxic and nephrotoxic effects of a combination of lithium carbonate and haloperidol. Arch Int Pharmacodyn Thera 1985;276:301312.Google Scholar
62. Lai, JS, Zhao, Z, Warsh, JJ, Li, PP. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol 2006;539:1826.Google Scholar
63. Nciri, R, Desmoulin, F, Allagui, MS et al. Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress. Int J Neuropsychopharmacol 2013;16:365376.Google Scholar
64. Scola, G, Laliberte, VL, Kim, HK et al. Vitis labrusca extract effects on cellular dynamics and redox modulations in a SH-SY5Y neuronal cell model: a similar role to lithium. Neurochem Int 2014;79:1219.Google Scholar